NCT02129582View on ClinicalTrials.gov

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 5, 2014

Primary Completion Date

March 15, 2019

Study Completion Date

March 5, 2020

Conditions
Acute Myeloid LeukemiaHematologic MalignanciesAcute Lymphocytic LeukemiaNon Hodgkin LymphomaHodgkin LymphomaMultiple MyelomaMyelodysplastic SyndromeChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaMyelofibrosisMyeloproliferative Syndrome
Interventions
RADIATION

total marrow irradiation

Undergo TMI

DRUG

fludarabine phosphate

Given IV

DRUG

busulfan

Given IV or PO

PROCEDURE

myeloid progenitor cell transplantation

Undergo allogeneic hematopoietic progenitor cell transplant

BIOLOGICAL

anti-thymocyte globulin

Given IV

DRUG

tacrolimus

Given IV or PO

DRUG

methotrexate

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

44106-5065

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02129582 - Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter